Zydus Lifesciences receives USFDA approval for Empagliflozin and Metformin Hydrochloride Tablets

14 Jul 2022 , 01:33 AM

Zydus Lifesciences has received final approval from the United States Food and Drug Administration USFDA to market Empagliflozin and Metformin Hydrochloride Tablets in the strengths of 5 mg500 mg 5 mg1000 mg 125 mg500 mg and 125 mg1000 mg US RLD Synjardy Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease The drug will be manufactured at the groups formulation facility at SEZ Ahmedabad India